Three major companies have announced their reduced prices for insulin. Lilly, Novo Nordisk and Sanofi are going to participate in the reduction of costs. Finally!
Starting April 1, 2023, Lilly will be capping the costs of insulin for individuals with commercial and without commercial insurance. An equivalent to Lantus will be launched and will be capped at $92 for a 5-pack of pens.
Starting May 1, 2023, Humalog will be reduced by 70% and its generic form will be available for $25 a vial.
Starting on January 1, 2024, Novo Nordisk will be reducing Novolog 70/30 and other insulins by 70%. For those without insurance, 3 vials or 2 (5 packs) of pens will be $99 a month.
Starting January 1, 2024, Sanofi, who manufactures Lantus will be reducing the price by 78% and people who use a co-pay assistance card will pay $35.
While there is still more work to be done in order to reduce the costs of all insulins, this progress is huge. The future looks promising for insulin users and with these efforts in the works, it can only get better from here!
Integrated Diabetes Services is the worldwide leader in one-on-one consulting for people who use insulin. Diabetes “coaching” services are available in-person and remotely via phone and the internet for children and adults.